GLP-1s Are More Than Weight Loss Drugs

If you've been following news about GLP-1 medications, you've probably heard Serena Williams weigh in. The tennis legend recently pushed back against the idea that these drugs are just a shortcut for people who want to lose weight. Her position: GLP-1s offer "so much more" than that.

She's not wrong. And if you're already taking one of these medications or thinking about starting, understanding the full scope of what they do matters for your health decisions.

What GLP-1 Medications Actually Do in Your Body

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. GLP-1 receptor agonists, the class of drugs that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), mimic and amplify this hormone's effects throughout the body.

Yes, that includes telling your brain you're full sooner. But these drugs also act on receptors in the heart, kidneys, liver, brain, and blood vessels. That's not a side effect. It's the mechanism.

When researchers started studying long-term outcomes, they found benefits that had nothing to do with the number on the scale. Those findings changed how cardiologists, nephrologists, and other specialists think about these medications.

The Cardiovascular Evidence Is Significant

The SELECT trial, published in the New England Journal of Medicine in 2023, enrolled over 17,000 adults with overweight or obesity and existing cardiovascular disease, but without diabetes. Participants on semaglutide had a 20% lower risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, compared to those on placebo.

That's a meaningful reduction. And it wasn't explained entirely by weight loss alone, which suggests the drug has direct protective effects on blood vessels and the heart.

For anyone with a family history of heart disease or who has already had a cardiac event, this data is worth discussing with your cardiologist, not just your primary care doctor.

What This Means Practically

If you're taking Wegovy or Ozempic primarily to lose weight and you also have cardiovascular risk factors, you may be getting a second layer of protection you didn't know about. That context is relevant when weighing the cost and commitment of long-term treatment.

Kidney Disease: An Emerging Area of Evidence

In 2024, the FDA approved semaglutide (under the brand name Ozempic) for reducing the risk of kidney disease progression and kidney-related death in adults with type 2 diabetes and chronic kidney disease. This approval was based on the FLOW trial, which showed a 24% reduction in major kidney disease events.

This was significant because kidney disease affects roughly 37 million Americans and often progresses silently. Having a medication that protects kidney function, on top of managing blood sugar or weight, adds real clinical value.

Researchers are now studying whether these kidney-protective effects extend to people without diabetes as well.

Fatty Liver Disease: A Quiet but Growing Problem

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, affects an estimated one in four adults globally. Until recently, there were no approved drug treatments.

Resmetirom was the first drug approved specifically for MASH (the more advanced inflammatory form), but semaglutide has shown promising data in this area too. Clinical trials have demonstrated that semaglutide can reduce liver fat, lower inflammation markers, and improve liver fibrosis scores.

Tirzepatide, the active ingredient in Mounjaro, has also shown strong results in MASH trials. For people who have been told they have elevated liver enzymes or fatty liver findings on imaging, this is worth raising with your gastroenterologist.

Sleep Apnea: Unexpected but Real

One of the more surprising findings from recent GLP-1 research involves sleep apnea. Tirzepatide was studied specifically in adults with obesity-related obstructive sleep apnea in the SURMOUNT-OSA trial.

The results showed clinically meaningful reductions in apnea events per hour, with some participants experiencing near-complete resolution of their sleep apnea symptoms. The FDA granted tirzepatide (Zepbound) approval for treating moderate-to-severe obstructive sleep apnea in adults with obesity in late 2024.

This matters because sleep apnea is linked to cardiovascular disease, cognitive decline, and metabolic dysfunction. Treating it effectively through a medication like tirzepatide addresses multiple health concerns at once.

Mental Health and Cognitive Effects: Early but Interesting

This area of research is newer and still evolving, so it comes with more caution. But several observational studies and early trial data suggest that GLP-1 medications may have effects on the brain that go beyond appetite suppression.

Some research has pointed to reductions in addictive behaviors, including alcohol use and smoking, in people taking these drugs. Others have looked at potential neuroprotective effects relevant to Alzheimer's disease risk, with trials currently underway.

None of this is settled science yet. But it reflects why researchers across specialties are paying attention to this drug class in a way that goes well beyond weight management.

Inflammation, Metabolic Health, and Blood Sugar Control

GLP-1 medications improve insulin sensitivity and reduce systemic inflammation, two factors that underlie dozens of chronic conditions. For people with prediabetes, these drugs can delay or prevent progression to type 2 diabetes.

The DREAM trial and subsequent research has shown that semaglutide substantially reduces hemoglobin A1c, a marker of long-term blood sugar control. And for people with type 2 diabetes, it remains one of the most effective tools available.

Even for people without diabetes, improved metabolic markers like lower fasting glucose, reduced triglycerides, and improved HDL cholesterol levels are commonly seen during GLP-1 treatment.

What This Means for Coverage, Cost, and Access

The broadening evidence base for GLP-1 medications is starting to influence coverage decisions. Several large employers and insurers who previously excluded GLP-1s for weight loss have begun reconsidering those policies as cardiovascular, kidney, and sleep apnea approvals stack up.

If your insurer denied coverage for weight loss, it may be worth asking your doctor whether a documented comorbidity, such as heart disease, sleep apnea, or prediabetes, qualifies you for coverage under a different indication. The same drug may be covered under one diagnosis code but not another.

Cost remains a real barrier for many patients. Brand-name semaglutide and tirzepatide list prices can reach $900 to $1,400 per month without insurance. Manufacturer savings programs, compounded alternatives through telehealth providers, and pharmacy discount options can significantly reduce that burden. Check the GLP-1 Coupons page for current options.

Choosing the right provider matters too, especially if you have multiple health conditions and need someone who will look at your full picture. Compare options at Best Providers.

Questions to Ask Your Doctor Before Starting or Continuing

Whether you're just starting to explore GLP-1 medications or have been on one for a while, these questions are worth raising at your next appointment.

• Do I have any conditions beyond weight that might benefit from GLP-1 treatment?
• Would my cardiovascular or kidney history qualify me for coverage under a different indication?
• Is semaglutide or tirzepatide better suited to my specific health profile?
• Are there specialist referrals I should consider, such as a cardiologist or nephrologist?
• What markers should we track over time to assess the full benefit I'm getting?

The conversation around GLP-1 medications has often centered on weight, which is understandable given the obesity epidemic. But framing these drugs only as weight loss tools leaves important information off the table.

The Bottom Line: Weight Loss Is the Entry Point, Not the Whole Story

Public figures like Serena Williams speaking openly about GLP-1 use serve a purpose. They shift the conversation from "are these drugs just for people who can't lose weight on their own" to "what is this class of medications actually capable of."

The science increasingly supports a broader view. Semaglutide and tirzepatide are not magic, and they come with real side effects, real costs, and the need for real medical oversight. But they are among the most studied drug classes in recent history, and the data continues to show effects across multiple organ systems.

If you've been hesitant about GLP-1 medications because you thought they were only about the scale, or if you've been dismissive because you don't need to lose much weight, it's worth revisiting that assumption with your doctor. Your cardiovascular risk, kidney health, liver function, and sleep quality are all relevant inputs.

And if you're already taking one of these medications, know that what's happening beneath the surface may be delivering more benefit than what you're tracking week to week.

Where to Go From Here

The most important next step is a conversation with a qualified provider who understands your full health picture, not just your BMI.

If you're still figuring out where to start, the Best Providers page on GLP-1.com compares telehealth and in-person options that prescribe GLP-1 medications, with details on cost, process, and what each provider evaluates.

If cost is your primary concern, the GLP-1 Coupons page tracks current manufacturer discounts, pharmacy savings programs, and compounding options that may bring monthly costs within reach.

The picture of what GLP-1 medications can do is still developing. But what's already on the table is well worth understanding, whatever your reason for reading this.